CAH

Business Context and Reporting Period

Company: Cardinal Health, Inc. (formerly Cardinal Distribution, Inc.)
Reporting Period: Fiscal Year Ended June 30, 1994
Business Overview: A national, full-service wholesaler distributing pharmaceuticals, surgical supplies, and health care products to hospitals, drug stores, and managed care facilities. The company operates through sixteen principal subsidiaries and provides value-added support services including computerized order entry and inventory management.
Key Event: On February 7, 1994, the Company completed a pooling-of-interests merger with Whitmire Distribution Corporation, significantly expanding its geographic footprint to the western and central United States. The Company also changed its fiscal year-end from March 31 to June 30 effective March 1, 1994.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 25% to $5.79 billion, driven by 20% internal growth and acquisitions (PRN Services and Solomons Company).
• Margin Compression: Gross margin percentage declined to 6.13% from 6.42% due to lower selling margins in a competitive market and reduced purchasing gains from lower drug price inflation.
• Unusual Items: Operating earnings were impacted by a $35.9 million nonrecurring charge for Whitmire Merger costs. In the prior year, earnings included a $13.5 million termination fee and $13.7 million in nonrecurring restructuring charges.
• Debt Reduction: Long-term obligations decreased by approximately $65.7 million, primarily due to the conversion of $74.9 million in Subordinated Debentures to equity and repayment of Whitmire's revolving credit facilities, partially offset by the issuance of $100 million in new 6.5% Notes due 2004.
• Liquidity: Net working capital increased to $471.1 million, supported by higher accounts payable and increased investments in inventory and receivables.

Guidance, Outlook, and Risks

• Outlook: Management expects gross margin rates to continue declining but at a more moderate pace. The company anticipates continued growth through acquisitions and internal expansion.
• Capital Resources: The Company maintains $296 million in available lines of credit. It filed a registration statement in August 1994 for a public offering of 5.25 million Class A Common Shares to finance working capital growth.
• Legal Risks: The Company is a defendant in consolidated class action antitrust lawsuits ("Brand Name Prescription Drug Litigation") alleging conspiracy to inflate prices via chargeback systems. Management believes the allegations are without merit and intends to contest them vigorously.
• Regulatory Environment: The industry faces pressure from healthcare reform legislation and cost containment efforts by payers, which may impact pricing and distribution models.
• Subsequent Acquisitions: Post-fiscal year, the Company acquired Humiston-Keeling, Inc. (July 1, 1994) and Behrens Inc. (July 18, 1994) to further expand its market presence.

Investor Verification Checklist

• Merger Integration Costs: Verify the actual realization of the estimated $35.9 million Whitmire Merger costs and the impact on future operating expenses.
• Margin Trends: Monitor the trajectory of gross margins given the competitive pressure and lower drug price inflation cited by management.
• Antitrust Litigation: Track the status of the "Brand Name Prescription Drug Litigation" and potential financial exposure.
• Debt Structure: Review the terms of the new $100 million 6.5% Notes due 2004 and the interest rate swap agreements hedging the 8% Notes due 1997.
• Acquisition Synergies: Assess the financial performance of recent acquisitions (Whitmire, PRN, Solomons, Humiston-Keeling, Behrens) to ensure projected synergies are realized.